Keywords: مهارکننده 5α-ردوکتاز; prostatic hyperplasia; dutasteride; finasteride; heart failure; drug-related side effects and adverse reactions; 5ARI; 5α-reductase inhibitor; BPH; benign prostatic hyperplasia; DHT; dihydrotestosterone;
مقالات ISI مهارکننده 5α-ردوکتاز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
Keywords: مهارکننده 5α-ردوکتاز; bladder neoplasms; 5-alpha reductase inhibitors; Finland; survival; adrenergic alpha-antagonists; 5-ARI; 5α-reductase inhibitor; BCa; bladder cancer; HILMO; Care Register for Health Care; SII; Social Insurance Institution of Finland; TURB; transurethral
Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features
Keywords: مهارکننده 5α-ردوکتاز; prostatic neoplasms; watchful waiting; 5-alpha reductase inhibitors; neoplasm grading; risk factors; 5-ARI; 5α-reductase inhibitor; AS; active surveillance; DRE; digital rectal examination; PSA; prostate specific antigen; REDEEM; Reduction with Dutaster
Change of the 5α/5β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride
Keywords: مهارکننده 5α-ردوکتاز; USP; urinary steroid profiling; GC/MS; gas chromatography/mass spectrometry; BPH; benign prostatic hyperplasia; DHT; dihydrotestosterone; DUT; dutasteride; 5AR; 5α-reductase; 5ARI; 5α-reductase inhibitor; FIN; finasteride; IPSS; International Prostate S
Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
Keywords: مهارکننده 5α-ردوکتاز; 5α-Reductase Inhibitor; Post-Finasteride Syndrome; Male Pattern Hair Loss; Androgenic Alopecia; Androgen Receptor; CAG Polymorphism; GGN Polymorphism; Erectile Dysfunction; Sexual Dysfunction; Loss of Libido; Finasteride Side Effects; Finasteride Safety;
Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist
Keywords: مهارکننده 5α-ردوکتاز; prostatic hyperplasia; adrenergic alpha-antagonists; physicians; primary care; 5-ARI; 5α-reductase inhibitor; AB; alpha blocker; BPH; benign prostatic hyperplasia; LIS; low income subsidy; PCP; primary care physician;
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use
Keywords: مهارکننده 5α-ردوکتاز; prostatic neoplasms; prostate-specific antigen; mass screening; 5α-reductase inhibitors; Finland; 5-ARI; 5α-reductase inhibitor; BPH; benign prostatic hyperplasia; DRE; digital rectal examination; FinRSPC; Finnish Randomized Study of Screening for Prost
Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics
Keywords: مهارکننده 5α-ردوکتاز; urinary bladder neck obstruction; lower urinary tract symptoms; adrenergic alpha-antagonists; 5-alpha reductase inhibitors; drug substitution; 5ARI; 5α-reductase inhibitor; α1-blocker; α1-adrenergic receptor blocker; BMI; body mass index; BOO; bladder
Risk Factors for Delayed Hematuria Following Photoselective Vaporization of the Prostate
Keywords: مهارکننده 5α-ردوکتاز; prostate; prostatic hyperplasia; lasers; anticoagulants; urination disorders; 5ARI; 5α-reductase inhibitor; CBI; continuous bladder irrigation; DH; delayed gross hematuria; ED; emergency department; ER; emergency room; PVP; photoselective vaporization of
Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ml after Treatment with 5α-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer
Keywords: مهارکننده 5α-ردوکتاز; early detection of cancer; prostatic neoplasms; prostate-specific antigen; finasteride; dutasteride; 5aR; 5α-reductase; 5aRI; 5α-reductase inhibitor; BPH; benign prostatic hyperplasia; CaP; prostate cancer; DRE; digital rectal examination; PSA; prostate
Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor
Keywords: مهارکننده 5α-ردوکتاز; Hybrid; Finasteride; Epristeride; 5α-reductase inhibitor; Combination principles;
Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study
Keywords: مهارکننده 5α-ردوکتاز; 5-alpha reductase inhibitors; dutasteride; prostatitis; 5ARI; 5α-reductase inhibitor; BPH; benign prostatic hyperplasia; CP; chronic prostatitis; CPCRN; Chronic Prostatitis Collaborative Research Network; CPPS; chronic pelvic pain syndrome; CPSI; Chronic
Benign Prostatic Hyperplasia Evaluation and Management by Urologists and Primary Care Physicians: Practice Patterns From the Observational BPH Registry
Keywords: مهارکننده 5α-ردوکتاز; prostate; prostatic hyperplasia; physician's practice patterns; primary health care; urology; 5ARI; 5α-reductase inhibitor; AB; α-blocker; AUA; American Urological Association; BPH; benign prostatic hyperplasia; DRE; digital rectal examination; I-PSS; I
Understanding Results
Keywords: مهارکننده 5α-ردوکتاز; evidence-based medicine; data interpretation; statistical; risk; risk assessment; decision support techniques; 5ARI; 5α-reductase inhibitor; NNT; number needed to treat;
Evaluating Use Patterns of and Adherence to Medications for Benign Prostatic Hyperplasia
Keywords: مهارکننده 5α-ردوکتاز; prostate; prostatic hyperplasia; medication adherence; Medicaid; adrenergic alpha-antagonists; 5-ARI; 5α-reductase inhibitor; AB; α-blocker; BPH; benign prostatic hyperplasia; LUTS; lower urinary tract symptoms; Medi-Cal; California Medicaid; MM; multip
What are the Views of Patients and Urologists on Benign Prostatic Hyperplasia and Its Management?
Keywords: مهارکننده 5α-ردوکتاز; α-blocker; 5α-reductase inhibitor; Benign prostatic hyperplasia; Lower urinary tract symptoms; Survey;
Optimising Assessment and Treatment Decisions for Men with BPH
Keywords: مهارکننده 5α-ردوکتاز; α-blocker; Benign prostatic hyperplasia; 5α-reductase inhibitor; Minimally invasive therapy; TURP;
Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment
Keywords: مهارکننده 5α-ردوکتاز; Progesterone metabolites; Dutasteride; 5α-Reductase; 5α-Reductase inhibitor; Hydroxysteroid oxidoreductases; 5α-Dihydroprogesterone; 3α-Dihydroprogesterone; Proliferation; Adhesion; Human breast cell lines; MCF-7; MCF-10A; Breast cancer; mRNA expressi